# Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

> **NCT03147885** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 43 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Extranodal Marginal Zone Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Indolent Adult Non-Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Waldenstrom Macroglobulinemia
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Extranodal Marginal Zone Lymphoma
- Refractory Follicular Lymphoma
- Refractory Mantle Cell Lymphoma
- Stage III Non-Hodgkin Lymphoma
- Stage IV Non-Hodgkin Lymphoma
- Transformed Recurrent Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT03147885
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-20
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03147885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03147885, "Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03147885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*